“We Need to Rethink the Whole Thing”: Jeff Shuren Will Aim High on MDUFA V-Linked Reforms

article image

The next user fee negotiation process, MDUFA V, kicks off next year, and it should be interesting. FDA device center director Jeff Shuren is signaling plans to seek big-ticket legislative reforms that he hopes will give his center more leeway to implement new regulatory frameworks, and to more fully engage in a global pre-market review program.

FDA doesn’t want to be timid in the next round of device user fee negotiations. That was made clear by device center director Jeff Shuren in the closing moments of The MedTech Conference, where he urged a packed room in Boston to “really think about, where do we want to be as an ecosystem” over the long term, in advance of the MDUFAV user fee reauthorization process that will kick off next year to reach final legislation before the current program expires in 2022.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to Market Pathways:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to Market Pathways
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: